期刊文献+

颗粒溶素在不同类型药疹患者中的表达

Expression of granulysin in patients with different types of drug eruption
原文传递
导出
摘要 目的比较不同类型药疹患者血清学及细胞中颗粒溶素表达差异。方法酶联免疫吸附试验(ELISA)和流式细胞仪分别检测7例中毒性表皮坏死松解症、5例Stevens—Johnson综合征进展期患者、8例多形红斑药疹患者、8例发疹型药疹患者及11例健康人血清及外周血T细胞中颗粒溶素的表达水平。利用SPSSl7.0进行统计学分析,两组均数比较采用随机或配对t检验,3组间比较采用ANOVA分析。结果中毒性表皮坏死松解症和Stevens-Johnson综合征急性期患者血清颗粒溶素水平为(0.196±0,079)μg/L,明显高于发疹型药疹患者[(0.022±0.003)μg,L]和健康对照[(0.013±0.005)μg/L],F=3.926,P〈0.05,但与多形红斑患者[(0.058±0,004)μg/L]相比差异无统计学意义。Stevens-Johnson综合征患者和中毒性表皮坏死松解症患者表达颗粒溶素的CD8+T细胞比例为(3.400±0.754)%,多形红斑组为(0.600±0.250)%,发疹型药疹组和健康对照组分别为(0.342±0.251)%和(0.054±0.024)%,4组间差异有统计学意义,F=11.4,P〈0.01。结论颗粒溶素在中毒性表皮坏死松解症、Stevens—Johnson综合征患者中表达水平较高,可能对该病急性期的鉴别诊断及预后评价具有潜在的应用价值。 Objective To compare the cellular and serum expression levels of granulysin among patients with different types of drug eruption. Methods Blood samples were collected from 7 patients with toxic epidermal necrolysis (TEN), 5 patients with acute Stevens-Johnson syndrome (SJS), 8 patients with erythema multiforme, 8 patients with exanthematic drug eruption, and 11 healthy controls. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) were performed to quantify the protein expression of granulysin in peripheral blood T cells and sera from these subjects, respectively. Data were processed by the SPSS17.0 software, and differences in these parameters were analyzed by one-way analysis of variance and independent or paired sample t-test. Results The serum level of granulysin in patients with TEN or acute SJS was significantly higher than that in those with exanthematic drug eruption and healthy controls ((0.196 ± 0.079) μg/L vs. (0.022 ± 0.003) μg/L and (0.013 ± 0.005 ) μg/L, F = 3.926, P 〈 0.05), but similar to that in those with erythema multiforme ( (0.058 ± 0.004 ) μg/L, P 〉 0.05). Significant differences were observed in the proportion of CD8+ T ceils expressing granulysin in peripheral blood mononuclear cells (PBMCs) between patients with TEN or acute SJS, erythema muhiforme, exanthematic drug eruption, and healthy controls ((3.400 ± 0.754)% vs. (0.600 ± 0.250)% vs. (0.342 ± 0.251)% vs. (0.054 ± 0.024)%, F = 11.4, P 〈 0.01 ). Conchtsions Granulysin is highly expressed in patients with TEN and SJS, which may have potential value for their differential diagnosis and prognosis evaluation at acute phase.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2013年第5期362-364,共3页 Chinese Journal of Dermatology
基金 陕西省科学技术研究发展计划项目(2011K12-03-07)
  • 相关文献

参考文献9

  • 1Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol, 2000, 136(3 ): 323-327.
  • 2Friedmann PS,Pickard C,Ardem-Jones M,et al. Drug-inducedexanthemata:a source of clinical and intellectual confusion. Eur JDermatol,2010,20(3):255-259.
  • 3高杨,付萌,史晓蔚,廖文俊,高琳,高天文,王刚,李承新,刘玉峰.重症药疹患者外周血药物特异性T细胞扩增及干扰素γ产生的研究[J].中华皮肤科杂志,2010,43(7):478-481. 被引量:2
  • 4Murata J,Abe R,Shimizu H,et al. Increased soluble Fas ligandlevels in patients with Stevens-Johnson syndrome and toxicepidermal necrolysispreceding skin detachment. J Allergy ClinImmunol,2008,122(5):992-1000.
  • 5阎伯龄,段昕所.药瘆与发疼性疾病的鉴别诊断.北京:北京出版社,1991:5-6.
  • 6Karoline Stur,Franz M. Soluble FAS Ligand:A DiscriminatingFeature between Drug-Induced Skin Eruptions and Vira Exan-themas. Journal of Investigative Dermatology,2007,127 (11):802-807.
  • 7李越,陈伟.Granulysin的研究进展[J].细胞与分子免疫学杂志,2002,18(6):676-677. 被引量:5
  • 8Pena SV,Krensky AM. Granulysin,a new human cytolyticgranule associated protein with possible involvement in cellmediated cytotoxicity. Semin Immunol,1997,9(2):117-125.
  • 9Chung WH,Hung SI,Yang JY,et al. Granulysin is a key mediatorfor disseminated keratinocyte death in Stevens-Johnson syndromeand toxic epidermal necrolysis. Nat Med,2008,14 (12):1343-1350.

二级参考文献25

  • 1江佳,翁孟武.干扰素γ释放试验诊断药疹的作用[J].中华皮肤科杂志,2006,39(10):602-604. 被引量:2
  • 2[1]Pena SV, Krensky AM. Granulysin, a new human cytolytic granule-associated protein with possible involvement in cell-mediated cytotoxicity[J]. Semin Immunol, 1997, 9(2):117-125.
  • 3[2]Manning WC, O'Farrell S, Goralski TJ, et al. Genomic structure and alternative spilicing of 519, a gene expressed late after T cell activation[J]. J Immunol, 1992, 148(12):4036-4042.
  • 4[3]Pena SV, Hanson DA, Carr BA, et al. Processing, subcellular localization and function of 519(granulysin), a human late T cell activation molecular with homology to small, lytic granule proteins[J]. J Immunol, 1997, 158:2680.
  • 5[4]Hanson DA, Kaspar AA, Poulain FR, et al. Biosynthesis of granulysin, a novel cytolytic molecule[J]. Mol Immunol, 1999, 36(7): 413- 422.
  • 6[5]Stenger S, Hanson DA, Teitelbaum R, et al. An antimicrobial activity of cytolytic T cells mediated by granulysin[J]. Science, 1998, 282:121-125.
  • 7[6]Dieli F, Troye-Blomberg M, Ivanyi J, et al. Granulysin-Dependent Killing of Intracellular and Extracellular Mycobacterium tuberculosis by Vgamma9/Vdelta2 T Lymphocytes[J]. J Infect Dis, 2001, 184(8):1082-1085.
  • 8[7]Wang Z, Choice E, Kaspar A, et al. Bactericidal and tumoricidal activities of synthetic peptides derived from granulysin[J]. J Immunol, 2000, 165:1486-1490.
  • 9[8]Stenger S, Rosat J-P, Bloom BR, et al. Granulysin: a lethal weapon of cytolytic T cells[J]. Immunol Today, 1999, 20(8):390-394.
  • 10[9]Gamen S, Hanson DA, Kaspar A, et al. Granulysin-induced apoptosis I. Involvement of at least two distinct pathways[J]. J Immunol, 1998, 161:1758-1764.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部